|Bid||19.07 x 800|
|Ask||19.21 x 1000|
|Day's Range||18.57 - 19.19|
|52 Week Range||16.21 - 52.43|
|Beta (5Y Monthly)||1.53|
|PE Ratio (TTM)||2.17|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ITOS
The latest analyst coverage could presage a bad day for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ), with the analysts...
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -87.50% and 56.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A, and GSK’s anti-PD-1 Jemperli (dostarlimab) - Enrolling patients with non-small cell lung cancer in a randomized Phase 2 trial evaluating the combination of inupadenant, an A2A receptor antagonist, with chemotherapy - Cash balance of $792MM as of June 30, 2022, expected to provide runway into 2026 to support differentiated clinical progra